Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Pfizer (NY: PFE )

25.53 -0.11 (-0.43%)
Official Closing Price Updated: 7:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pfizer

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Why Is Moderna Stock Trading Higher On Monday?
Moderna's Laval, Quebec, facility received a Drug Establishment License from Health Canada, allowing it to produce mRNA vaccines domestically by 2025. The site will manufacture COVID-19, RSV, and flu... 
Via Benzinga
Exposures COVID-19
Relay Therapeutics Advances Towards Pivotal Trial As It Shares Encouraging Breast Cancer Data In Heavily Pretreated Patients
Monday, Relay Therapeutics Inc. (NASDAQ:RLAY) shared interim data for RLY-2608 from ReDiscover study, an ongoing first-in-human study, to evaluate the safety, tolerability, pharmacokinetics,... 
Via Benzinga
3 No-Brainer Dividend Stocks With Yields Above 5% You Can Buy Now and Hold at Least a Decade
It's not hard to see how these well-seasoned businesses could deliver heaps of passive income to patient investors. 
Via The Motley Fool
3 No-Brainer Dividend Stocks to Buy in September
These stocks pay great dividends and could be long-term winners. 
Via The Motley Fool
Bicycle Therapeutics' Lead Cancer Candidate's Has High-Opportunity, Analyst Initiates With Bullish Tone
RBC Capital initiates coverage on Bicycle Therapeutics, highlighting Zelenectide's potential in oncology with improved safety over competitors. The analyst projects ~$2 billion in peak sales by 2033... 
Via Benzinga
A Closer Look at Pfizer's Options Market Dynamics
Via Benzinga
FDA Battles Backlog of Drug Factory Inspections Since COVID-19
FDA faces inspection backlog with serious public health implications, as critical drug manufacturing plants remain unchecked. 
Via Benzinga
Exposures Product Safety
What's Going On With Penny Stock Blood Cancer-Focused Vor Biopharma On Friday?
Vor Biopharma reveals promising Phase 1/2 study results for AML treatment, and it is planning FDA pivotal trial discussions. 
Via Benzinga
Exposures Product Safety
A Few Years From Now, You'll Wish You Had Bought This Undervalued Stock
This big drugmaker's current challenges present an excellent buying opportunity for forward-thinking investors. 
Via The Motley Fool
Fake Ozempic Targets Weight-Loss Market: Forged Batches An International Concern
Criminals distribute fake Ozempic by forging batch numbers. Novo Nordisk suspects one source in global counterfeiting operation. Other drugs also affected. 
Via Benzinga
Psychedelic Drugs Market Set To Grow By $1.37B By 2028, Driven By Mental Health Disorders And AI Integration
The global psychedelic drugs market is projected to grow by USD 1.37 billion by 2028, driven by mental health needs and AI advancements in drug development. 
Via Benzinga
Topics Artificial Intelligence
Exposures Artificial Intelligence
Why Walgreens Boots Alliance Fell Another 22% in August
The retail pharmacy giant faces ever-mounting headwinds. 
Via The Motley Fool
Ascendis Pharma Faces Challenges With Skytrofa And Yorvipath Pricing: Analysts Weigh In
Ascendis Pharma reported disappointing Q2 sales of $38.76 million, missing the consensus of $92.7 million. Key updates included a higher-than-expected U.S. price for Yorvipath and a delayed cash flow... 
Via Benzinga
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
EQNX::TICKER_START (NASDAQ:SBFM),(NASDAQ:MRNA),(NYSE:PFE),(NASDAQ:VIR),(NASDAQ:INO) EQNX::TICKER_END 
Via FinancialNewsMedia
Exposures COVID-19
Global Coronavirus Therapeutics Market Size Projected to Exceed $16 Billion By the End of 2031
From FN Media Group LLC
Via GlobeNewswire
3 Bargain-Priced Growth Stocks for Fall 2024
Investors can leverage market volatility to uncover undervalued companies with solid fundamentals and significant growth potential. 
Via MarketBeat
Topics Economy
Exposures COVID-19 Economy
Therma Bright Congratulates John Patton, PhD of InStatin on Receiving the Prestigious Charles G. Thiel Award
Toronto, Ontario--(Newsfile Corp. - September 4, 2024) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) ("Therma" or the "Company"), a... 
Via Newsfile
UK, Taiwan Approve Moderna's Updated COVID-19 Shot
The Medicines and Healthcare Products Regulatory Agency has approved Moderna's updated COVID-19 vaccine targeting the JN.1 variant, available for eligible groups through the NHS autumn program and for... 
Via Benzinga
Exposures COVID-19
Pfizer And Valneva Partnered Lyme Disease Vaccine Shows Effectiveness As Booster Shot In Mid-Stage Study
Valneva and Pfizer released data from their Phase 2 study of the Lyme disease vaccine candidate VLA15, showing strong immune response and safety profile after a second booster dose, with seroconversion... 
Via Benzinga
Vaxcyte, Shoals Technologies, Polestar Automotive, Applied Optoelectronics And Other Big Stocks Moving Higher On Tuesday
Via Benzinga
Bacterial Infections Vaccine Developer Vaxcyte's Pneumococcal Shot Shows Promise in Mid-Stage Trial, Stock Shoots Higher
Vaxcyte announced positive topline results from its Phase 1/2 study of VAX-31, a 31-valent pneumococcal conjugate vaccine candidate, showing strong immune responses and safety comparable to Pfizer's... 
Via Benzinga
Vaxcyte Catapults 34% As It Looks To Take On Pfizer In A $10 Billion Market
The company is looking to take on Pfizer in the massive pneumococcal conjugate vaccine market. 
Via Investor's Business Daily
Why Is BridgeBio Pharma Stock Trading Higher On Friday?
BridgeBio Pharma presented additional data from its Phase 3 ATTRibute-CM study of acoramidis in ATTR-CM at the European Society of Cardiology 2024, showing increased serum TTR levels in participants... 
Via Benzinga
Alnylam Pharmaceuticals Stock Falls After Detailed Vutrisiran Data For A Condition With Stiff Heart Muscles
Alnylam Pharmaceuticals shares drop as detailed results from the HELIOS-B Phase 3 study of vutrisiran for ATTR-CM reveal mixed outcomes. Reductions in mortality and cardiovascular events were presented... 
Via Benzinga
Alnylam Plummets, Reversing 50% Gain This Year, As Pfizer Rival Lags Expectations
The company is hoping to rival Pfizer's approved treatment for cardiomyopathy. 
Via Investor's Business Daily
2 Incredibly Cheap Growth Stocks to Buy Now
The market has been tougher on these companies than some, but that could be a golden opportunity for the right investor. 
Via The Motley Fool
2 Incredibly Cheap Healthcare Stocks to Buy Now
Top healthcare stocks are a great addition to any portfolio. 
Via The Motley Fool
The 9 Pharma Stocks To Watch — Including Viking, Roche And Amgen — Amid The Fast-Growing Obesity Drug Race
The race to develop the next big obesity treatment is on with leaders Lilly and Novo trying to keep their top slots. 
Via Investor's Business Daily
Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference
From Pfizer Inc.
Via Business Wire
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
These underappreciated dividend payers offer yields above 4% at recent prices. 
Via The Motley Fool
Topics Stocks
Exposures US Equities
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.